Changchun High-Tech Industries (000661.SZ): Polyethylene Glycol Recombinant Human Growth Hormone Injection Approved for Additional Indications Supplement Application.

04/03/2025

GMT Eight

Changchun High-Tech Industries (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for a supplemental application for the recombinant human growth hormone injection (trade name: Jinsai Zeng) of polyethylene glycol. Specifically, the approved specifications for 54IU/9.0mg/1.0ml/bottle have been expanded to include the following indications that have already been approved in China: for growth disorders in girls with gonadal dysgenesis (Turner Syndrome); and for idiopathic short stature (ISS). The approved specifications for 27IU/4.5mg/0.5ml/bottle have been expanded to include the indication for slow growth in children caused by endogenous growth hormone deficiency.

On March 3rd, PRU(02378) purchased approximately 241.66 million pounds to repurchase about 33.1 million shares.

Suning Clearing and Hong Kong Exchanges and Clearing Limited sign a cooperation memorandum of understanding. Yu Weiwen: This is a significant milestone for Suning Clearing to become another important cornerstone of Asia's ICSD.

Contact: contact@gmteight.com

Changchun High-Tech Industries (000661.SZ): Polyethylene Glycol Recombinant Human Growth Hormone Injection Approved for Additional Indications Supplement Application.

RECOMMEND

HK Stock Market Move | KINGKEY FIN INT (01468) opened nearly 5% higher and is considering setting up investment opportunities and services involving cryptocurrency license regulation.

HK Stock Market Move | ALPHAMAB-B (09966) surged more than 11% at the opening, expected to achieve annual profit for the first time with a profit of no less than 1.5 billion yuan.

HK Stock Market Move | XD INC (02400) opened more than 11% higher after the profit celebration, with an expected net profit of up to 940 million yuan last year, turning losses into profits year-on-year.